5-Alpha Reductase Inhibitors Increase the Risk of Aggressive Prostate Cancer: Fact or Myth
Gerald L. Andriole, Jr., MD, challenges misconceptions about 5-ARIs in urology, focusing on their role in prostate cancer.
Read MoreSelect Page
Posted by Gerald L. Andriole, Jr., MD | Feb 2025
Gerald L. Andriole, Jr., MD, challenges misconceptions about 5-ARIs in urology, focusing on their role in prostate cancer.
Read MorePosted by Gerald L. Andriole, Jr., MD | Feb 2025
Gerald L. Andriole, Jr., MD, discusses the evolving role of micro-ultrasound in prostate cancer detection.
Read MorePosted by Mark N. Painter, CPMA, MBS | Oct 2024
Mark N. Painter, CPMA and Michael Burnett, Chief Operating Officer at Kansas City Urology Care, discuss upcoming 2025 Medicare Part D changes and how it will affect urology patients. This 12-minute discussion goes into detail of each new update to Medicare Part D, how it can affect patients who are in need of grants, subsidies or assistance, and how urology practices can aid patients in adopting and taking advantage of these new updates.
Read MorePosted by Gerald L. Andriole, Jr., MD | May 2023
Gerald L. Andriole, Jr., MD, Director of Urology in the National Capital Region at the Brady Urologic Institute at Johns Hopkins University, discusses the uses of microultrasound in prostate assessment using the PRIMUS (Prostate Risk Identification using Micro-UltraSound) protocol, which allows most prostate ducts to be visualized and tissue patterns appreciated. He compares the accuracy of PRIMUS to its conventional analog, PRIMAD. Dr. Andriole cites research that suggests novice mircroultrasound practitioners can become adept at interpreting images and identifying lesions after as few as 30-40 scans.
He compares images and biopsy results from conventional ultrasound, microultrasound, and multiparametric magnetic resonance imaging (mpMRI) to illustrate the accuracy of microultrasound. Dr. Andriole also shares data that supports the use of systematic biopsy, micro-ultrasound targeted biopsy, and MRI together to identify the greatest proportion of clinically significant prostate cancer. However, Dr. Andriole concludes that while microultrasound is a promising tool for future identification of prostate risk, current studies like the OPTIMUM trial have yet to determine whether it can fully replace conventional diagnostic MRIs.
Read MorePosted by Gerald L. Andriole, Jr., MD | Jan 2023
Gerald L. Andriole, Jr., MD, discusses micro-ultrasound, describing it as fast, flexible, and accurate, with real-time visualization.
Read More